Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt N/A
EDAP's Cash-to-Debt is ranked higher than
73% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. EDAP: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
EDAP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37  Med: N/A Max: No Debt
Current: N/A
Equity-to-Asset 0.52
EDAP's Equity-to-Asset is ranked lower than
62% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. EDAP: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
EDAP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.4 Max: 1
Current: 0.52
0.25
1
Interest Coverage 0.32
EDAP's Interest Coverage is ranked lower than
100% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. EDAP: 0.32 )
Ranked among companies with meaningful Interest Coverage only.
EDAP' s Interest Coverage Range Over the Past 10 Years
Min: 0.32  Med: 7.63 Max: 7.63
Current: 0.32
0.32
7.63
Piotroski F-Score: 6
Altman Z-Score: 2.68
WACC vs ROIC
7.46%
44.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 4.37
EDAP's Operating Margin % is ranked higher than
55% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. EDAP: 4.37 )
Ranked among companies with meaningful Operating Margin % only.
EDAP' s Operating Margin % Range Over the Past 10 Years
Min: -18.31  Med: -12.16 Max: 4.37
Current: 4.37
-18.31
4.37
Net Margin % 27.76
EDAP's Net Margin % is ranked higher than
97% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. EDAP: 27.76 )
Ranked among companies with meaningful Net Margin % only.
EDAP' s Net Margin % Range Over the Past 10 Years
Min: -53.64  Med: -18.89 Max: 27.76
Current: 27.76
-53.64
27.76
ROE % 74.59
EDAP's ROE % is ranked higher than
99% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. EDAP: 74.59 )
Ranked among companies with meaningful ROE % only.
EDAP' s ROE % Range Over the Past 10 Years
Min: -111.74  Med: -26.8 Max: 74.59
Current: 74.59
-111.74
74.59
ROA % 33.40
EDAP's ROA % is ranked higher than
99% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. EDAP: 33.40 )
Ranked among companies with meaningful ROA % only.
EDAP' s ROA % Range Over the Past 10 Years
Min: -31.62  Med: -13.18 Max: 33.4
Current: 33.4
-31.62
33.4
ROC (Joel Greenblatt) % 74.78
EDAP's ROC (Joel Greenblatt) % is ranked higher than
91% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. EDAP: 74.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EDAP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -65.88  Med: -36.06 Max: 74.78
Current: 74.78
-65.88
74.78
3-Year Revenue Growth Rate -10.30
EDAP's 3-Year Revenue Growth Rate is ranked lower than
79% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. EDAP: -10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EDAP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.3  Med: -2.35 Max: 10.9
Current: -10.3
-17.3
10.9
3-Year EPS without NRI Growth Rate -48.70
EDAP's 3-Year EPS without NRI Growth Rate is ranked lower than
92% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EDAP: -48.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EDAP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.7  Med: -19.4 Max: 253.7
Current: -48.7
-48.7
253.7
GuruFocus has detected 1 Warning Sign with Edap TMS SA $EDAP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EDAP's 10-Y Financials

Financials (Next Earnings Date: 2017-04-04)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EDAP Guru Trades in Q1 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q2 2016

EDAP Guru Trades in Q2 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q3 2016

EDAP Guru Trades in Q3 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q4 2016

EDAP Guru Trades in Q4 2016

Robert Bruce 1,045,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:OTCPK:PHMZF, NAS:EYES, NAS:NVTR, NAS:SPNE, NAS:SRTS, NAS:SPAN, OTCPK:AVMXF, NAS:IRMD, NAS:VIVE, OTCPK:TITXF, OTCPK:BTCY, OTCPK:VICA, AMEX:ELMD, NAS:MSON, NAS:ETRM, NAS:TNDM, NAS:MGCD, NAS:AVGR, OTCPK:LCTC, OTCPK:BLOZF » details
Traded in other countries:EDA.Germany,
Edap TMS SA is a holding company. The Company through its divisions HIFU and UDS,develops, produces and markets minimally invasive medical devices for urological diseases. Its divisions operate in Europe, the Americas, Asia and the rest of the world.

Edap TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS. Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2013, the HIFU division's patent portfolio contained 36 patents consisting of 16 in the United States, 18 in the European Union and Japan and 2 in Israel and the rest of the world. The Company belongs to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy. The Company and its products are regulated in the United States by the FDA under a number of statutes including the Federal Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
PE Ratio 6.43
EDAP's PE Ratio is ranked higher than
97% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 26.64 vs. EDAP: 6.43 )
Ranked among companies with meaningful PE Ratio only.
EDAP' s PE Ratio Range Over the Past 10 Years
Min: 5.1  Med: 21.84 Max: 52.09
Current: 6.43
5.1
52.09
PE Ratio without NRI 6.43
EDAP's PE Ratio without NRI is ranked higher than
97% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. EDAP: 6.43 )
Ranked among companies with meaningful PE Ratio without NRI only.
EDAP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.03  Med: 21.84 Max: 52.09
Current: 6.43
5.03
52.09
PB Ratio 2.76
EDAP's PB Ratio is ranked higher than
59% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. EDAP: 2.76 )
Ranked among companies with meaningful PB Ratio only.
EDAP' s PB Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.81 Max: 18.27
Current: 2.76
0.49
18.27
PS Ratio 1.78
EDAP's PS Ratio is ranked higher than
68% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. EDAP: 1.78 )
Ranked among companies with meaningful PS Ratio only.
EDAP' s PS Ratio Range Over the Past 10 Years
Min: 0.3  Med: 1.52 Max: 5.97
Current: 1.78
0.3
5.97
EV-to-EBIT 12.22
EDAP's EV-to-EBIT is ranked higher than
79% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 22.27 vs. EDAP: 12.22 )
Ranked among companies with meaningful EV-to-EBIT only.
EDAP' s EV-to-EBIT Range Over the Past 10 Years
Min: -5776  Med: -5.5 Max: 190.3
Current: 12.22
-5776
190.3
EV-to-EBITDA 12.22
EDAP's EV-to-EBITDA is ranked higher than
67% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. EDAP: 12.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
EDAP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5776  Med: -5.5 Max: 190.3
Current: 12.22
-5776
190.3
Current Ratio 2.76
EDAP's Current Ratio is ranked higher than
59% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. EDAP: 2.76 )
Ranked among companies with meaningful Current Ratio only.
EDAP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2.33 Max: 3.92
Current: 2.76
1.27
3.92
Quick Ratio 2.23
EDAP's Quick Ratio is ranked higher than
61% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. EDAP: 2.23 )
Ranked among companies with meaningful Quick Ratio only.
EDAP' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.07 Max: 3.51
Current: 2.23
1.07
3.51
Days Inventory 72.82
EDAP's Days Inventory is ranked higher than
79% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. EDAP: 72.82 )
Ranked among companies with meaningful Days Inventory only.
EDAP' s Days Inventory Range Over the Past 10 Years
Min: 72.82  Med: 107.9 Max: 130.3
Current: 72.82
72.82
130.3
Days Sales Outstanding 106.42
EDAP's Days Sales Outstanding is ranked lower than
79% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. EDAP: 106.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
EDAP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 106.42  Med: 187.9 Max: 249.93
Current: 106.42
106.42
249.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.40
EDAP's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. EDAP: -11.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EDAP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23  Med: -6.45 Max: 2.9
Current: -11.4
-23
2.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 3.60
EDAP's Price-to-Net-Current-Asset-Value is ranked higher than
75% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. EDAP: 3.60 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EDAP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.29  Med: 3.66 Max: 19.45
Current: 3.6
0.29
19.45
Price-to-Tangible-Book 3.06
EDAP's Price-to-Tangible-Book is ranked higher than
59% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 4.36 vs. EDAP: 3.06 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EDAP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.22  Med: 2.53 Max: 16.75
Current: 3.06
0.22
16.75
Price-to-Intrinsic-Value-Projected-FCF 3.65
EDAP's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
70% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. EDAP: 3.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EDAP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.41  Med: 5.33 Max: 20.14
Current: 3.65
0.41
20.14
Price-to-Median-PS-Value 1.18
EDAP's Price-to-Median-PS-Value is ranked lower than
54% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. EDAP: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EDAP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 0.65 Max: 3.93
Current: 1.18
0.17
3.93
Price-to-Graham-Number 1.55
EDAP's Price-to-Graham-Number is ranked higher than
60% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. EDAP: 1.55 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EDAP' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.08  Med: 0.86 Max: 3.76
Current: 1.55
0.08
3.76
Earnings Yield (Greenblatt) % 8.16
EDAP's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. EDAP: 8.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EDAP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 6 Max: 189209.4
Current: 8.16
0.5
189209.4

More Statistics

Revenue (TTM) (Mil) $40.75
EPS (TTM) $ 0.41
Beta0.97
Short Percentage of Float1.18%
52-Week Range $2.25 - 4.80
Shares Outstanding (Mil)28.73

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 38 45 51 56
EPS ($) 0.19 0.04 0.10 0.15
EPS without NRI ($) 0.19 0.04 0.10 0.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EDAP

Headlines

Articles On GuruFocus.com

More From Other Websites
EDAP's Ablatherm® Robotic HIFU: Clinical Results Support High-Intensity Focused Ultrasound (HIFU)... Mar 22 2017
EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017 Mar 14 2017
EDAP's Long Term Academic HIFU Partner INSERM LabTAU Designated Center of Excellence by the Focused... Mar 08 2017
EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. Mar 06 2017
Q4 2016 Edap Tms SA Earnings Release - After Market Close Mar 03 2017
EDAP's Ablatherm® Robotic HIFU Treatments Performed at University of Minnesota Feb 27 2017
EDAP Announces Preliminary Unaudited Full Year 2016 Revenue Feb 23 2017
EDAP to Exclusively Distribute LABORIE’s Medical Measurement Systems Urodynamic Products in Japan Jan 23 2017
EDAP to Host Meetings with Investors During JP Morgan Healthcare Conference Week Jan 04 2017
EDAP Reports Superior Outcomes of Focal Ablatherm-HIFU Compared to Robotic Radical Prostatectomy Dec 19 2016
EDAP to Report Third Quarter 2016 Financial Results on November 17, 2016 Nov 03 2016
EDAP TMS SA (EDAP) Sees Hammer Chart Pattern: Time to Buy? Oct 12 2016
EDAP‘s Ablatherm® Robotic HIFU Positioned as Efficient Option for Unilateral Prostate Ablation in... Oct 11 2016
EDAP Installs Ablatherm Robotic® HIFU at Leading Academic Medical Center Sep 12 2016
EDAP TMS SA :EDAP-US: Earnings Analysis: Q1, 2016 By the Numbers : August 30, 2016 Aug 30 2016
EDAP Reports 69% Growth in HIFU Revenues and Operating Profit for First Half 2016 Aug 25 2016
EDAP's Ablatherm® Robotic HIFU Treats First Patient at Henry Ford Hospital in Detroit Aug 22 2016
EDAP to Report Second Quarter 2016 Financial Results on August 25, 2016 Aug 11 2016
EDAP Announces First HIFU Treatments Performed in New England Jun 16 2016
First HIFU patient treated at Allied Urological Services in New York City with the Ablatherm®... Jun 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)